| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Early diagnosis of peritoneal dissemination in gastric cancer patients is important because of the high recurrence rate of this disease. In this study, we examined the usefulness of a peritoneal recurrence genetic diagnosis panel (gene panel) consisting of cancer stem cell and cancer specific markers for gastric cancer (GC). The study was examined the peritoneal lavage fluid of 470 GC patients. The Peritoneal recurrence free survival of the gene panel positive group was significantly worse than that of the gene panel negative group. Genetic markers were independent prognostic factors for peritoneal recurrence. In patients administered with chemotherapeutic drugs (Paclitaxel), the result of the gene panel showed a significant association with peritoneal dissemination. Our results indicate that the newly developed gene panel is a useful tool in the early diagnosis of GC and effective monitoring of the therapeutic effects of chemotherapy in GC patients.
|
